{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-027733","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.983718+00:00","generated_at":"2026-05-26T03:48:51.203959+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Relay Therapeutics Q4 net loss $0.45/sh; cash $781M; Phase 3 ReDiscover-2 trial mid-2025","bullets":["Net loss of $76.0M ($0.45/sh) in Q4 2024 vs $83.5M ($0.67/sh) in Q4 2023.","Cash, cash equivalents and investments of $781.3M at Dec 31, 2024, expected to fund operations into H2 2027.","Phase 3 ReDiscover-2 trial for RLY-2608 + fulvestrant in PI3Kα-mutated breast cancer to initiate mid-2025; 540 patients, PFS primary endpoint.","Phase 1b data showed 11.4-month median PFS and 39% ORR in 2L patients with PI3Kα-mutated HR+/HER2- advanced breast cancer.","Full year 2024 revenue $10.0M (down from $25.5M); net loss $337.7M ($2.36/sh)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-027733","json":"https://secwatch.observer/filing/0000950170-25-027733.json","markdown":"https://secwatch.observer/filing/0000950170-25-027733.md","text":"https://secwatch.observer/filing/0000950170-25-027733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017025027733/0000950170-25-027733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017025027733/rlay-20250226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:48:51.203959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}